At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 127 enrolled
Drug / intervention
Hydromorphone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study
In Brief
A Phase 4 clinical trial evaluating Hydromorphone, Prochlorperazine, and 1 other intervention for Migraine. Completed, enrolled 127 participants across 1 site.
Detailed Summary
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy in migraine. Prochlorperazine will be combined with diphenhydramine to prevent adverse events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartMar 2015
First PostedMar 2015
Primary CompletionJun 2016
Study CompletionOct 2016
TodayJul 2026
First PostedMar 17, 2015
Enrollment StartMar 1, 2015
Primary CompletionJun 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.3 years ago
Interventions
Hydromorphonedrug
Prochlorperazinedrug
Diphenhydraminedrug